Randomized clinical trial results for donepezil in Alzheimer's disease: is the treatment glass half full or half empty?
Farlow
Martin R
MR
Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.
D000203:Activities of Daily Living; D000329:Advertising; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D016265:Conflict of Interest; D000077265:Donepezil; D004311:Double-Blind Method; D004345:Drug Industry / Q000191:economics; D004465:Economic Competition; D019317:Evidence-Based Medicine; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D040541:Marketing; D018697:Nootropic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil